Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  pb!!

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

pb!!

21 Posts
Pagina: 1 2 »» | Laatste | Omlaag ↓
  1. [verwijderd] 3 april 2008 14:09
    PRESS RELEASE: Crucell Announces First In Man Study With New Adenovirus VectorLast update: 4/3/2008 8:01:12 AM

    = -

    Recombinant adenovirus 26 vector avoids pre-existing immunity and is
    used in new HIV vaccine


    Leiden, The Netherlands, 3 April 2008 - Dutch biotechnology company
    Crucell N.V. today announced that the novel recombinant adenovirus
    serotype 26 (rAd26) vector, which is jointly developed by Crucell and
    the Beth Israel Deaconess Medical Center (BIDMC), will be used in a
    phase I clinical study to test a new HIV vaccine. The rAd26 vector
    is specifically designed to avoid the pre-existing immunity to the
    more commonly used adenovirus serotype 5 (Ad5), which has recently
    shown limitations as an HIV vaccine vector.

    The rAd26 vaccine is the first HIV vaccine candidate that emerges
    from the Integrated Preclinical/Clinical AIDS Vaccine Development
    (IPCAVD) program, which brings together researchers from academia and
    industry in an effort to accelerate the development of promising
    HIV/AIDS vaccines. Crucell, Harvard Medical School (HMS) and the
    BIDMC participate in this program, which is sponsored by the National
    Institutes of Health (NIH).

    The phase I clinical study will be conducted at the Brigham and
    Women's Hospital (BWH) in Boston and will focus on assessing the
    safety and immunogenicity of the vaccine. The study will involve 48
    healthy volunteers.

    "The rAd26 vaccine vector has been selected for its particularly low
    seroprevalence in humans and for its potential immunogenicity and
    protective efficacy as was shown in preclinical studies", says Dan H.
    Barouch, MD, PhD, Associate Professor of Medicine at BIDMC and HMS
    and Principal Investigator in the IPCAVD program.

    Jaap Goudsmit, Chief Scientific Officer at Crucell: "The rAd26
    vector, as part of our AdVac® technology program, is designed to
    overcome the problem of pre-existing immunity in humans against the
    most commonly used recombinant vaccine vector, adenovirus serotype
    5."

    Antibodies to Ad5, a common cold virus, are widespread among people
    of all ages and are known to lower the immune response to Ad5-based
    vaccines, thereby impairing the efficacy of these vaccines.

    "The rAd26 vector does not regularly occur in the human population
    and antibodies to this vector are rare. The rAd26 vector therefore is
    efficacious in eliciting good T and B cell responses", Goudsmit
    continues. "We are excited about the first in man study of this newly
    developed vector, that could provide a solution to the issues that
    raised from previous HIV vaccine trials."

  3. flosz 3 april 2008 14:19
    Poetsen poetsen... lijkt wel een schoonmaakbedrijf.
    **********************

    4Q 07/ 1Q 08....................

    This study is not yet open for participant recruitment.

    ClinicalTrials.gov processed this record on April 02, 2008
    clinicaltrials.gov/ct2/show/NCT00618605
    www.iex.nl/forum/topic.asp?forum=228&...
    crucell.yourbb.nl/viewtopic.php?f=7&t...
    www.iex.nl/forum/topic.asp?forum=228&...
  8. flosz 3 april 2008 14:57
    Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity
    www.iex.nl/forum/topic.asp?forum=228&...

    AdVac®/PER.C6® Technology-Based HIV Vaccine: The Investigational New Drug Application (IND) for Phase I of the trial with Harvard Medical School (supported by the NIH) has been approved by the FDA in January 2008. Phase I of the trial is expected to start before the end of the first quarter of 2008.
    investors.crucell.com/C/132631/PR/200...

    Op 30 oktober 2006 hield hoogleraar Armoede-gerelateerde infectieziekten prof. dr. Jaap Goudsmit een lezing met als titel Malaria, TB en aids de wereld uit rond 2015: geen kans op zonder vaccins. www.uva.nl/maagdenhuisopmaandag/objec...
    www.aeras.org/news/documents/Thalerle...

    J Virol. 2008 Mar 12
    Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys.
    Liu J, Ewald BA, Lynch DM, Denholtz M, Abbink P, Lemckert AA, Carville A, Mansfield KG, Havenga MJ, Goudsmit J, Barouch DH.
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215; Crucell Holland BV, 2301 CA, Leiden, The Netherlands; New England Primate Research Center, Southborough, MA 01772.
    Recombinant adenovirus serotype 5 (rAd5) vaccine vectors for HIV-1 and other pathogens have been shown to elicit antigen-specific cellular immune responses. Rare serotype rAd vectors have also been constructed to circumvent pre-existing anti-Ad5 immunity and to facilitate the development of novel heterologous rAd prime-boost regimens. Here we show that rAd5, rAd26, and rAd48 vectors elicit qualitatively distinct phenotypes of cellular immune responses in rhesus monkeys and can be combined as potent heterologous prime-boost vaccine regimens. While rAd5-Gag induced primarily IFN-gamma+ and IFN-gamma+/TNF-alpha+ T lymphocyte responses, rAd26-Gag and rAd48-Gag induced higher proportions of IL-2+ and polyfunctional IFN-gamma+/TNF-alpha+/IL-2+ T lymphocyte responses. Priming with the rare serotype rAd vectors proved remarkably effective for subsequent boosting with rAd5 vectors. These data demonstrate that the rare serotype rAd vectors elicited phenotypically distinct T lymphocyte responses as compared with rAd5 vectors and suggest the functional relevance of polyfunctional CD8+ and CD4+ T lymphocyte responses. Moreover, qualitative differences in cellular immune responses may prove critical in determining the overall potency of heterologous rAd prime-boost regimens.
    PMID: 18337575
    www.iex.nl/forum/topic.asp?forum=228&...

    Government sees overhaul of AIDS vaccine effort
    Tue Mar 25, 2008

    23 MARCH 2008
    Enough is Enough
    Instead of continuing to squander hundreds of millions of dollars on a futile quest for an HIV vaccine, focus AIDS spending on prevention, testing and treatment
    It is time to stop the waste.

    AIDS Vaccine Research: A Reevaluation
    A. Fauci, Director, NIAID
    www3.niaid.nih.gov/news/events/meetin...

    Vaccine Research Status
    Carl W. Dieffenbach, Ph.D.
    Director, Division of AIDS
    National Institute of Allergy and
    Infectious Diseases
    March 25, 2008
    www3.niaid.nih.gov/news/events/meetin...

    crucell.yourbb.nl/viewtopic.php?f=7&t...
  10. [verwijderd] 3 april 2008 15:07
    Crucell start fase 1 klinische studie adenovirus voor HIV
    03-04-2008 14:51:02

    Amsterdam (BETTEN FINANCIAL NEWS) - Crucell start met een nieuw recombinant adenovirus een klinische fase 1 studie voor de test van een nieuw HIV-vaccin. Dat heeft het biotechnologiebedrijf donderdag bekendgemaakt in een persbericht. Het gaat om de rAd26 vector, die is ontwikkeld in samenwerking met Beth Israel Deaconess Medical Center (BIDMC).

    Het rAd26-vaccin is speciaal ontwikkeld om de immuniteit tegen het vaker gebruikte adenovirus serotype 5 (Ad5), een veelvoorkomend verkoudheidsvirus, te omzeilen. De studie zal worden uitgevoerd in een ziekenhuis in Boston onder 48 gezonde vrijwilligers.

    Het rAd26-vaccin is het eerste kandidaat-medicijn dat voortkomt uit het Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) programma.
  11. flosz 3 april 2008 15:24
    quote:

    Dirk R. Wijnen schreef:

    The rAd26 vaccine is the first HIV vaccine candidate that emerges
    from the Integrated Preclinical/Clinical AIDS Vaccine Development
    (IPCAVD) program, which brings together researchers from academia and
    industry in an effort to accelerate the development of promising
    HIV/AIDS vaccines.
    NIAID Integrated Preclinical/Clinical AIDS Vaccine
    Development (IPCAVD) Program
    • Vectors selected for advancement into clinical trials:
    �� Ad26 - optimal rare serotype Ad vector
    �� Ad5HVR48 - optimal chimeric Ad vector
    • Antigen selected for phase I studies of prototype vectors:
    • Clade A HIV-1 Env gp140 (Gary Nabel, VRC, NIH)
    • Plans for a complete multivalent vaccine in progress
    • HER.96 cells selected for GMP manufacturing (Crucell, IAVI)
    www.hivvaccineenterprise.org/_dwn/dba...

    Leiden, The Netherlands, August 1, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has, in collaboration with Harvard Medical School, been awarded a US$ 19.2 million (€ 15.9 million) grant from the US National Institutes of Health (NIH) to develop new adenovirus vector-based vaccines against HIV/AIDS. Crucell will receive US$ 8.1 million (€ 6.7 million) for the further development of its AdVac® technology.

    The program at Harvard and Crucell has focused for two years on the development of AdVac®, which incorporates next-generation vaccine vectors based on rare human adenoviruses. The technology is central to Crucell's malaria and tuberculosis vaccine programs. The new five-year grant, awarded under the project title of 'Novel Adenovirus Vector-Based Vaccines for HIV-1', will complement Crucell's involvement in the adenovirus vector-based HIV vaccine programs of the International AIDS Vaccine Initiative (IAVI) and Merck. The AdVac®-based IAVI program is at an advanced preclinical stage; the Merck program is currently in Phase II proof-of-concept studies in humans. It is based on Merck's in-house vector system and Crucell's PER.C6® production technology.

    Principal investigator for the grant project will be Dr Dan Barouch, of Harvard's Beth Israel Deaconess Medical Center. Dr Jaap Goudsmit, Crucell's Chief Scientific Officer, will lead the efforts at Crucell.

    "This NIH award for further development of rare human adenovirus-based vectors validates Crucell's AdVac® technology and recognizes the accomplishments of the joint program at Harvard and Crucell over the last two years," said Dr Goudsmit.

    The rationale for the joint program's vaccines has been published in the August issue of the Journal of Virology in a joint article entitled: Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity (JVI, August 2005; Vol. 79/15: p9694-9701).
  12. flosz 4 april 2008 08:33
    Phase 1 trial begins in Boston
    BOSTON – A phase 1 clinical trial to test a novel HIV/AIDS vaccine has begun at Brigham and Women’s Hospital (BWH). This new vaccine aims to overcome the problem of preexisting immunity to common vaccine vectors, which is thought to be a major problem in the developing world.
    “This study will involve 48 healthy volunteers who will receive either two or three immunizations and who will be followed to assess the safety and immunogenicity of the vaccine,” explains Lindsey R. Baden, MD, Assistant Professor of Medicine at BWH and Harvard Medical School and Protocol Chair for the study.
    The vaccine consists of a replication-incompetent, recombinant adenovirus serotype 26 (rAd26) vector encoding an HIV-1 envelope gene.
    “The rAd26 vaccine vector was selected for its particularly low seroprevalence in human populations and for its potent immunogenicity and protective efficacy in preclinical studies,” explains Dan H. Barouch, MD, PhD, Associate Professor of Medicine at Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School and Principal Investigator of the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program that developed the vaccine. This program is sponsored by the Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
    Manufactured by the Dutch biotechnology company Crucell Holland BV, the rAd26 vaccine is the first HIV-1 vaccine candidate to emerge from the IPCAVD initiative, which brings together investigators from academia and industry in an effort to accelerate the development of promising HIV/AIDS vaccine candidates. The novel strategy used in developing this vaccine enables researchers to circumvent preexisting immunity to the adenovirus serotype 5, the virus responsible for the common cold, which has recently shown limitations as an HIV-1 vaccine vector.
    “The rAd26 vector does not regularly occur in the human population and human antibodies to this vector are rare,” explains Jaap Goudsmit, Chief Scientific Officer at Crucell. “The rAd26 vector therefore is efficacious in eliciting good T and B cell responses.”
    AIDS remains one of the world’s most devastating health problems, with an estimated 33.2 million people living with HIV/AIDS and 2.5 million new infections reported in 2007 alone.
    www.eurekalert.org/pub_releases/2008-...
  13. [verwijderd] 4 april 2008 09:00
    MARKET TALK: Crucell; voorname rol in vaccinsector - GS


    AMSTERDAM (Dow Jones)--Het koersdoel van Crucell wordt door Goldman Sachs verhoogd naar EUR11,4 van EUR11. De zakenbank denkt dat de omzet van het griepvaccin zal herstellen en schroeft daarom zijn verwachting voor het bedrijf op. Vanwege een stabiele omzet en een houdbare winstgevendheid bevindt Crucell zich in een positie een voorname rol te spelen bij consolidatie in de vaccinsector. Goldman Sachs handhaaft het neutral advies. Crucell sloot donderdag op EUR10,16. (EBA)



    Dow Jones Nieuwsdienst: +31 20 5890270, amsterdam@dowjones.com



    (END) Dow Jones Newswires

    April 04, 2008 02:52 ET (06:52 GMT)

  14. flosz 4 april 2008 09:48
    Stukje geschiedenis erbij:
    IAVI Grants Harvard Researchers License To Use AIDS Vaccine Production Technology

    6 March 2006

    New York / Boston, March 16, 2006 - The International AIDS Vaccine Initiative (IAVI) and Beth Israel Deaconess Medical Center (BIDMC) jointly announced an agreement whereby IAVI will provide BIDMC researchers with a non-exclusive, non-commercial research and development license to use AdVac® technology, an adenovirus-based vaccine production technology, for AIDS vaccine development.

    Under the terms of the agreement, IAVI will offer the use of the technology at no cost to BIDMC. The AdVac® technology was licensed by IAVI from Crucell, a Dutch biotechnology company. IAVI and BIDMC will jointly monitor progress made by the use of the technology for potential application to the AIDS vaccine field. BIDMC is a major teaching hospital of Harvard Medical School.

    The technology provides a platform for BIDMC researchers to manufacture new adenovirus vector-based vaccine candidates for clinical trials. Adenoviruses are commonly used as vectors or shuttles in the design of AIDS vaccines. The BIDMC program represents an innovative approach in the AIDS vaccine field by identifying and developing unique adenovirus vectors able to circumvent pre-existing immunity, which could reduce the potential effectiveness of commonly used adenovirus vectors. BIDMC and Crucell have a long-lasting collaboration for the development of adenovirus vector-based vaccines. This program is funded by an Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program grant from the National Institutes of Health (NIH).

    "BIDMC is an important partner in the field of AIDS vaccine research and IAVI is providing this technology to support their program and advance the field's development of promising AIDS vaccine candidates," said Wayne Koff, Ph.D., IAVI senior vice president and chief of vaccine research. "IAVI is committed to sharing such technology with research teams throughout the world to accelerate progress and the development of an AIDS vaccine."

    "We plan to apply this critical technology to BIDMC's adenovirus vector development program," said Dan H. Barouch, M.D., Ph.D., BIDMC principal investigator and senior scientist. "It will greatly facilitate our ability to advance promising adenovirus vector-based HIV-1 vaccine candidates into clinical trials."

    The IAVI-BIDMC agreement underscores the importance of bringing together scientific expertise and resources of industry, academia, government, and non-profits to speed the development of an AIDS vaccine.

    "We have long-standing relationships with both IAVI and BIDMC in which our AdVac® technology has played a pivotal role," commented Jaap Goudsmit, MD, PhD, Crucell's Chief Scientific Officer. "We are very pleased that these two partners have now come together with our technology to further the vital advancement of adenovirus-based AIDS vaccine development."

    IAVI's scientific program researches and develops AIDS vaccine candidates through partnerships or agreements with more than 20 biotechnology, pharmaceutical, academic and government institutions worldwide.

    About BIDMC

    Beth Israel Deaconess Medical Center is a major patient care, teaching and research affiliate of Harvard Medical School, and ranks fourth in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a founding member of the Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.harvard.edu/.

    Crucell verleent IAVI exclusieve licentie voor het gebruik van AdVac® technologie voor AIDS vaccin

    Leiden, 14 september 2004 - Het Nederlandse biotechnologiebedrijf Crucell N.V. en het International AIDS Vaccine Initiative (IAVI) hebben een exclusieve licentieovereenkomst getekend om met behulp van Crucell's AdVac® technologie een AIDS vaccin te ontwikkelen. Naast financiering van ontwikkelingsactiviteiten ontvangt Crucell substantiële aanvangs-, jaarlijkse en 'milestone' betalingen en royalty's van IAVI, over de omzet van het HIV-vaccin na marktintroductie. Verdere financiële gegevens werden niet bekendgemaakt.

    Crucell's AdVac® technologie heeft in een aantal gezamenlijke studies met Harvard Medical School veelbelovende resultaten laten zien voor de productie van een vaccin tegen AIDS. Crucell gebruikt de AdVac® technologie ook voor het produceren van een vaccin tegen malaria in samenwerking met GlaxoSmithKline, het Walter Reed Army Institute of Research en het National Institute of Allergy and Infectious Diseases van de Amerikaanse NIH, evenals voor een vaccin tegen TBC in samenwerking met de Aeras Global TB Vaccine Foundation. Crucell's AdVac® technologie is een innoverende technologie om een vaccin in het lichaam van de patiënt te brengen. Met de AdVac® technologie kunnen ook vaccins worden ontwikkeld die een sterkere immuunrespons geven dan met andere technologieën en die dus effectiever kunnen zijn.

    "IAVI is continu op zoek naar betere nieuwe productprogramma's in de strijd tegen AIDS. In dat kader zijn wij verheugd met Crucell samen te werken en passen wij hun essentiële technologie toe om het ontwikkelingsproces van een AIDS vaccin te bevorderen," zei Emilio Emini, Senior Vice President, Vaccine Development van IAVI.

    "Deze overeenkomst bevestigt de waarde van onze AdVac® technologie voor het ontwikkelen van vaccins," aldus Jaap Goudsmit, Chief Scientific Officer van Crucell. "Wij zijn er trots op een bijdrage te kunnen leveren aan de strijd tegen HIV. Volgens ons werken wij nu met onze twee verschillende technologieën, PER.C6® - waarmee Merck al een kandidaat-vaccin heeft ontwikkeld - en AdVac® aan programma's die allebei een serieuze kans maken tot een succesvol AIDS-vaccin te leiden."

    Volgens de Wereld Gezondheidsorganisatie WHO werden in 2003 bijna 5 miljoen mensen besmet met HIV - het grootste aantal dat ooit in een jaar werd besmet sinds de start van de epidemie. Naar schatting leven nu 38 miljoen mensen wereldwijd met HIV. Meer dan 20 miljoen mensen zijn aan AIDS overleden sinds in 1981 de eerste gevallen werden geconstateerd.
    www.iex.nl/forum/topic.asp?forum=228&...
  15. [verwijderd] 4 april 2008 09:57
    MARKET TALK: Crucell; nieuwe vector wellicht miljardenproduct


    AMSTERDAM (Dow Jones)--Crucell maakte donderdag bekend een vector ontwikkeld te hebben samen met diakonessenziekenhuis Beth Israel om een nieuw vaccin tegen hiv te testen. SNS denkt dat Crucell in de toekomst een partner nodig heeft voor de verdere ontwikkeling van dit vaccin, aangezien de tweede en derde fase uitgebreider zullen zijn. Wanneer er in de eerste fase positieve resultaten geboekt worden, zal Crucell geen moeite hebben met het vinden van een partner aangezien dit hiv vaccin potentieel miljarden dollars kan opleveren. SNS heeft een koopadvies op Crucell met koersdoel EUR17,50. Omstreeks 9.50 uur noteert het aandeel 0,9% hoger op EUR10,25, terwijl de Midkap met 0,1% stijgt. (EBA)



    Dow Jones Nieuwsdienst: +31 20 5890270, amsterdam@dowjones.com



    (END) Dow Jones Newswires

    April 04, 2008 03:55 ET (07:55 GMT)

  17. flosz 4 april 2008 11:16
    Nature 452, 503 (3 April 2008)

    Broken promises

    Intense public support for clinical research can be a mixed blessing — and the hunt for a vaccine against AIDS offers an important lesson for many biomedical initiatives on what can go wrong.
    Last year's failed clinical trial for Merck's HIV vaccine led many to claim that AIDS vaccine research is in crisis. And at a meeting last week in Bethesda, Maryland, to examine how the field should proceed, discussion centred on the need for a "mid-course correction", as Warner Greene, director of the Gladstone Institute of Virology and Immunology in San Francisco, put it.
    The large-scale trial for Merck's candidate vaccine was well-designed and had been launched with considerable optimism. Yet the vaccine not only failed to lower patients' viral loads, it actually boosted the risk of infection in some groups. And worse, there are few strikingly different vaccine candidates in the pipeline ready for human trials. The PAVE 100 trial for a vaccine candidate similar to Merck's has already been cut in size, and discussions are taking place on whether the trial should go ahead at all.
    But if the AIDS vaccine field is in crisis, it is partly a crisis of its own making — one that holds lessons for many other areas of biomedical research. Decisions to move Merck's vaccine candidate and a previous failed candidate into clinical trials were based only partly on science. Also a factor was the field's need to show the public that progress is being made, thereby justifying the millions of dollars it receives from philanthropists and taxpayers. Historically, AIDS research has been afforded especially strong public support in the United States, but that means it works under an unusually intense public microscope. When promised results are not delivered, it's a double blow to the field, setting back the search for therapies while eroding public support.
    This is an important lesson for other fields, most notably those, such as autism, Parkinson's and stem-cell research, that are funded by a new breed of philanthropic organizations and agencies that use a more 'business-like' management model. The end-point and milestone-driven funding model used by these organizations has become increasingly fashionable, as has their practice of setting more directed research priorities at the outset.
    But there are consequences of the business-like approach that cannot be ignored. One is that trade-offs inevitably have to be made — often at the expense of basic research. The AIDS model provides a perfect example of this. When times are flush, as they were at the turn of this century, there is enough money to support clinical and basic researchers alike. When times become lean, as they are now, basic science loses out to the infrastructure that has been committed to clinical trials and 'big science' initiatives, such as the US$300-million Center for HIV–AIDS Vaccine Immunology. The US National Institute of Allergy and Infectious Diseases, the leading player in the US AIDS initiative, is now spending slightly more of its extramural AIDS-vaccine budget on testing vaccines than on discovering new candidates. As a result, the development pipeline has run dry of new ideas. To the agency's credit, it recognizes the problem and its director, Anthony Fauci, has pledged to "turn the knob in the direction of discovery" (see page 516).
    The other consequence of setting explicit milestones is the risk of public backlash when the results aren't delivered. AIDS vaccine research has made numerous promises it could not keep, such as when President Bill Clinton declared in 1997 that the nation would produce an AIDS vaccine within a decade. With every failure, public scrutiny grows. On 23 March, for instance, an article by the non-profit AIDS Healthcare Foundation appeared in The Baltimore Sun calling for an end to clinical trials for AIDS vaccines.
    Yet rather than learning from AIDS research, other fields are repeating its mistakes. The California Institute for Regenerative Medicine, for example, has promised to deliver "clinical proof-of-principle that transplanted cells derived from pluripotent cells can be used to restore function for at least one disease" by the end of its ten-year mandate. If this goal isn't met, the state's public, which voted to create and fund the institute, is likely to wonder whether its investment was worthwhile.
    Researchers have no choice but to reach out to the public for support. But when they do so, they do not serve themselves well by promising results they cannot deliver.
    www.nature.com/nature/journal/v452/n7...

    Published online 2 April 2008 | Nature 452, 516 (2008) | doi:10.1038/452516a
    News in Brief
    Back to basics for HIV vaccine development
    The US programme to develop an HIV vaccine will shift funding back towards basic research and away from clinical trials of candidate vaccines, officials at the National Institutes of Health announced last week.
    The decision follows the discontinuation last year of trials for Merck's candidate HIV vaccine, in which participants showed higher rates of HIV infection than the unvaccinated population. Merck's was one of only three vaccines to make it to large-scale clinical trials. A second had already failed, and there are doubts about the ability of the third to stimulate the immune system.
    The vaccine pipeline needs refilling, National Institute of Allergy and Infectious Diseases director Anthony Fauci said on 25 March. “We need to turn the knob in the direction of discovery — that is unambiguous.”
    www.nature.com/news/2008/080402/full/...
  18. forum rang 4 Lingus 4 april 2008 11:25
    quote:

    flosz schreef:

    Bullocks!
    Dit opgeklopt geleuter is precies wat de handelaartjes nodig hebben om de boel tzt weer eens goed uit te zuigen.
    Eigenlijk wel mee eens, maar wat er nu gebeurt is een ommekeer in het sentiment. De fantasie keert weer terug in de koers, niet alleen door dit bericht, maar ook door andere ontwikkelingen de laatste tijd.
  20. flosz 12 april 2008 19:20
    Van IV, by donnbonn.

    Boston Trial to Test New HIV/AIDS Vaccine
    Its ability to trigger an immune response where none existed is key to research

    Posted 4/11/08
    FRIDAY, April 11 (HealthDay News) -- A new HIV/AIDS vaccine designed to overcome the problem of preexisting immunity to common vaccine vectors is being tested in an early clinical trial at Brigham and Women's Hospital in Boston.
    Preexisting immunity is believed to be a major problem in developing nations.
    There will be 48 healthy volunteers taking part in the trial of the vaccine, which consists of a replication-incompetent, recombinant adenovirus serotype 26 (rAd26) vector encoding an HIV-1 envelope gene.
    Each volunteer will receive either two or three immunizations, and then be monitored to assess the safety of the vaccine and its ability to trigger an immune response.
    The rAd26 vaccine was developed by the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program, sponsored by the U.S. National Institute of Allergy and Infectious Diseases. The program brings together academic and industry researchers to accelerate development of promising HIV/AIDS vaccine candidates.
    The vaccine, the first HIV-1 vaccine candidate to emerge from the IPCAVD program, is made by Dutch biotechnology company Crucell Holland B.V.
    The approach used in developing the rAd26 vaccine enables researchers to circumvent preexisting immunity to serotype 5, the virus responsible for the common cold. This virus has recently shown limitations as an HIV-1 vaccine vector.
    "The rAd26 vector does not regularly occur in the human population, and human antibodies to this vector are rare. The rAd26 vector therefore is efficacious in eliciting good T and B (immune) cell responses," Jaap Goudsmit, chief scientific officer at Crucell, said in a prepared statement.
    About 33.2 million people worldwide are living with HIV/AIDS, and there were 2.7 million new infections reported in 2007.
    health.usnews.com/usnews/health/healt...
    www.investorvillage.com/smbd.asp?mb=2...
21 Posts
Pagina: 1 2 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 860,01 -0,62%
EUR/USD 1,0655 +0,11%
FTSE 100 7.895,85 +0,24%
Germany40^ 17.714,20 -0,69%
Gold spot 2.392,50 +0,55%
NY-Nasdaq Composite 15.282,01 -2,05%

Stijgers

WDP
+3,12%
Kendrion
+2,92%
EBUSCO...
+2,67%
Vopak
+2,61%
NX FIL...
+2,17%

Dalers

JUST E...
-5,11%
TomTom
-4,68%
Fugro
-4,30%
ASMI
-4,00%
BESI
-3,64%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!